Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

NCT00509548 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: TG100801

Sponsor

TargeGen